Added to YB: 2026-04-15
Pitch date: 2026-04-13
ARVN [neutral]
Arvinas, Inc.
+3.68%
current return
Author Info
Contrarian Cashflows publishes a monthly deep dive on a new value stock. Sign up for the newsletter.
Company Info
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Market Cap
$692.1M
Pitch Price
$10.61
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.14
P/E
-9.49
EV/Sales
0.06
Sector
Pharmaceuticals
Category
value
Monday Delight: 13/04/2026 - Arvinas, Inc.
ARVN (quick overview): Biotech using proprietary PROTAC platform for protein degradation therapeutics. Trades at 0.2x EV/Sales, 5.7x P/E ex-R&D, near net cash. Repurchased 10% shares in 2025 while cutting opex. Cash runway through 2028 for pipeline development. Revenue from collaborations, licensing, milestones vs product sales.
Read full article (1 min)